Area of research
Infectious Diseases · Hepatology
Research interest
Research interests include Hepatitis C virus research, HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, and HIV Research and Treatment.
Differential decline of SARS-CoV-2-specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID-19.
Scars are frequently found as late sequelae in individuals affected by the 2022 mpox outbreak.
No evidence of asymptomatic monkeypox infection in a highly sexually active MSM population in Austria.
Flow Cytometry-Based Measurement of Antibodies Specific for Cell Surface-Expressed Folded SARS-CoV-2 Receptor-Binding Domains.
Mpox in people with advanced HIV infection: a global case series
Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy
A homozygous AP3D1 missense variant in patients with sensorineural hearing loss as the leading manifestation.
Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium
Saturated very long-chain fatty acids regulate macrophage plasticity and invasiveness
Combined assessment of S- and N-specific IL-2 and IL-13 secretion and CD69 neo-expression for discrimination of post-infection and post-vaccination cellular SARS-CoV-2-specific immune response.
Immunological imprint of COVID-19 on human peripheral blood leukocyte populations.
PD-1 blocking antibodies moonlighting as killers.
Cause‐specific mortality after diagnosis of cancer among HIV‐positive patients: A collaborative analysis of cohort studies
Unreported Missense Mutation in the Dimerization Domain of ADA2 Leads to ADA2 Deficiency Associated with Severe Oral Ulcers and Neutropenia in a Female Somalian Patient-Addendum to the Genotype-Phenotype Puzzle.
Low seroprotection rate for meningococcus serogroup C in the adult HIV-1-infected population in Austria.
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma.
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling.
Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1.
Prevalence of Skin-specific Autoantibodies in HIV-infected Patients and Uninfected Controls.
Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)
Targeting CD20 in Melanoma Patients at High Risk of Disease Recurrence